Condition
Neuroendocrine Carcinoma of Pancreas
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (1)
P 2 (1)
Trial Status
Unknown2
Withdrawn1
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06893783Phase 2Recruiting
Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients
NCT03623984Early Phase 1WithdrawnPrimary
Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers
NCT05641233Phase 1UnknownPrimary
Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy
NCT01703650Unknown
Role of Perfusion CT in Pancreatic Cancer
Showing all 4 trials